1. Home
  2. SMSI vs AKTX Comparison

SMSI vs AKTX Comparison

Compare SMSI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith Micro Software Inc.

SMSI

Smith Micro Software Inc.

HOLD

Current Price

$0.63

Market Cap

15.3M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.35

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMSI
AKTX
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3M
14.4M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
SMSI
AKTX
Price
$0.63
$0.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
113.3K
1.3M
Earning Date
11-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$18,359,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$46.15
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.26
52 Week High
$1.95
$1.73

Technical Indicators

Market Signals
Indicator
SMSI
AKTX
Relative Strength Index (RSI) 49.26 31.07
Support Level $0.60 $0.29
Resistance Level $0.64 $0.36
Average True Range (ATR) 0.03 0.07
MACD 0.01 -0.00
Stochastic Oscillator 85.37 25.71

Price Performance

Historical Comparison
SMSI
AKTX

About SMSI Smith Micro Software Inc.

Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: